Clinical Outcomes and Treatment After Drug-Eluting Stent Failure: The Absence of Traditional Risk Factors for In-Stent Restenosis

Background— The optimal percutaneous treatment of drug-eluting stent (DES) in-stent restenosis (ISR) and the correlates for recurrent DES ISR remain unclear. Methods and Results— From 2003 to 2008, 563 patients presenting with recurrent symptoms of ischemia and angiographic ISR after DES implantation were included. Of these, 327 were treated with re-DES (58.1%), 132 underwent vascular brachytherapy (23.4%), and 104 were treated with conventional balloon angioplasty (18.5%). Variables associated with target lesion revascularization at 1 year were explored by individual proportional hazard models. This population presents a high prevalence of comorbidities, including diabetes (43.7%), previous myocardial infarction (MI) (45.8%), coronary bypass graft surgery (39.2%), chronic renal failure (18.8%), and heart failure (17.3%). Baseline clinical characteristics were balanced among the 3 groups; however, patients undergoing vascular brachytherapy presented with more complex lesions and a higher prevalence of prior stent/vascular brachytherapy failure than did the rest of the population. The overall incidence of recurrent DES failure at 1-year follow-up was 12.2%, which was similar among the 3 groups (P=0.41). The rate of the composite end point (death, Q-wave-MI and target lesion revascularization) at 1-year follow-up was 14.1% for re-DES, 17.5% for vascular brachytherapy, and 18.0% for conventional balloon angioplasty (P=0.57). After univariable analysis tested the traditional known covariates related to ISR, none of them were associated with repeat target lesion revascularization. Conclusions— Recurrence of ISR after DES treatment failure is neither infrequent nor benign, and optimal therapy remains unclear and challenging. Given the absence of traditional risk factors for ISR in this population, further research is required to elucidate both the correlates involved in DES ISR and the optimal treatment for this condition.

[1]  A. Kastrati,et al.  Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.

[2]  D. Baim,et al.  Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. , 2008, JACC. Cardiovascular interventions.

[3]  G. Lemesle,et al.  Vascular brachytherapy for patients with drug-eluting stent restenosis. , 2008, Journal of interventional cardiology.

[4]  G. Stone,et al.  Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. , 2007, The Journal of invasive cardiology.

[5]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[6]  K. Kent,et al.  Treatment of drug‐eluting stent restenosis with the same versus different drug‐eluting stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[8]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[9]  A. Colombo,et al.  Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. , 2007, American heart journal.

[10]  D. Desilvey.  Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2007, The American journal of geriatric cardiology.

[11]  Raghava R. Gollapudi,et al.  Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. , 2006, The American journal of cardiology.

[12]  K. Kent,et al.  Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.

[13]  Shile Huang,et al.  Predicted mechanisms of resistance to mTOR inhibitors , 2006, British Journal of Cancer.

[14]  N. Weissman,et al.  An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. , 2006, American Journal of Cardiology.

[15]  J. Moses,et al.  Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. , 2006, Journal of the American College of Cardiology.

[16]  P. Teirstein,et al.  Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.

[17]  G. Stone,et al.  Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.

[18]  P. Teirstein,et al.  Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. , 2005, The Journal of invasive cardiology.

[19]  D. Simon,et al.  Molecular Basis of Restenosis and Drug-Eluting Stents , 2005, Circulation.

[20]  Gregg W Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[21]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[22]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[23]  N. Weissman,et al.  The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. , 2001, American heart journal.

[24]  George Dangas,et al.  Update on In-stent Restenosis. , 2001, Current interventional cardiology reports.

[25]  C. Morillo,et al.  Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. , 2001, Journal of the American College of Cardiology.

[26]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[27]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[28]  B. Gersh.  Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients , 2009 .